{"id":"NCT04227704","sponsor":"Washington University School of Medicine","briefTitle":"Ketamine to Prevent PPD After Cesarean","officialTitle":"Postpartum Depression After Cesarean Delivery: Ketamine as a Preventative Intervention: A Feasibility Pilot-study","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-11-12","primaryCompletion":"2021-08-09","completion":"2021-08-09","firstPosted":"2020-01-14","resultsPosted":"2023-01-26","lastUpdate":"2023-01-26"},"enrollment":25,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"PREVENTION"},"conditions":["Postpartum Depression"],"interventions":[{"type":"DRUG","name":"Ketamine 50 MG/ML","otherNames":[]},{"type":"DRUG","name":"Control","otherNames":[]}],"arms":[{"label":"Control","type":"PLACEBO_COMPARATOR"},{"label":"Ketamine SC","type":"EXPERIMENTAL"},{"label":"Ketamine IVI","type":"EXPERIMENTAL"}],"summary":"The investigators plan to randomise participants to receive ketamine or placebo control subcutaneously or by 40-minute intravenous infusions and will follow them up for 42 days to assess the incidence of postpartum depression. This feasibility pilot study is designed to explore the adequacy of the study procedures and tolerability of the interventions.","primaryOutcome":{"measure":"The Prevalence of Postpartum Depression in the Study Population, as Defined as EPDS Greater Than 10 Out of 30","timeFrame":"42 days postpartum","effectByArm":[{"arm":"Control","deltaMin":4,"sd":null},{"arm":"Ketamine SC","deltaMin":2,"sd":null},{"arm":"Ketamine IVI","deltaMin":5,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":4},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["36271352"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":7},"commonTop":["Nausea","Pruritus","Sedation","Vomiting","Shivering"]}}